Infratil Limited · NZX:IFT
Infratil — Corporate Update (October 2026)
5 slides from Infratil's corporate update, Oct 7, 2026
Slide 1: CDC Independent Valuation – 30 September 2026
7 October 2026 For personal use only CDC Independent Valuation – 30 September 2026 CDC’s independent valuation was broadly flat with a mid-point valuation of A$18.5 billion at 30 September 2026. Continued progress in customer contracting and the development of CDC’s capacity pipeline was offset by t
Slide 2: CDC Independent Valuation 30 September 2026
CDC personal use only INDEPENDENT VALUATION 30 SEPTEMBER 2026
Slide 3: CDC Independent Valuation Update – 30 September 2026
CDC Independent Valuation Update – 30 September 2026 • CDC’s independent valuation was broadly flat with a mid-point valuation of A$18.5 billion at 30 September 2026. • Continued progress in customer contracting and the development of CDC’s capacity pipeline was offset by the macroeconomic impact of
Slide 4: Independent Valuation Assumptions
Independent Valuation Assumptions Valuation Methodology 30 September 2026 30 June 2026 Primary valuation methodology DCF using FCFE DCF using FCFE personal use only (with a cross check to market multiples and precedent (with a cross check to market multiples and precedent transactions) transactions)
Slide 5: CDC Development Pipeline
CDC Development Pipeline Leasable Capacity Pipeline September 2026 June 2026 by Region, rounded1 (MW) • Leasable operating and under construction capacity remained unchanged this quarter as development continued across multiple sites. Operating capacity personal use only • Australian future build ca